The crawling, buzzing, have-to-move-NOW feeling in the legs at 11pm is one of those symptoms that sounds almost made up until it is happening to you every single night. What nobody told me — or most women — is that this is a hormonal story as much as a neurological one, and that realisation alone changes everything about how to approach it.
Learn more about Rose →Estrogen acts as a natural modulator of dopamine synthesis and receptor sensitivity, particularly in the nigrostriatal and mesolimbic pathways that govern movement control. As estrogen levels decline in perimenopause, dopamine activity in these pathways becomes less stable, and RLS is fundamentally a dopamine-deficiency-adjacent condition — which is why dopamine agonists are the frontline pharmaceutical treatment. This hormonal-dopamine link explains why many women develop RLS for the first time in their late 40s without any other obvious trigger.
Progesterone and its neurosteroid metabolite allopregnanolone bind to GABA-A receptors in the central nervous system, producing a sedating, anti-anxiety effect that also quiets sensory hyperactivity. When progesterone drops erratically in perimenopause, that calming buffer is removed, leaving sensory neurons in the spinal cord more excitable and more likely to generate the uncomfortable sensations that define RLS. This is part of why RLS symptoms in perimenopausal women often feel worse during the luteal phase or after an anovulatory cycle when progesterone is lowest.
Iron in the brain is not optional for the dopamine system: iron is a cofactor for tyrosine hydroxylase, the enzyme that makes dopamine, and low brain iron is a well-established driver of RLS even when serum ferritin looks borderline normal. Estrogen upregulates the expression of duodenal iron transporters and influences hepcidin, the hormone that controls iron storage and release, meaning that as estrogen falls, iron uptake and utilization can become less efficient. Women in perimenopause who are still having heavy or irregular periods face a double hit — losing iron through bleeding while simultaneously absorbing it less effectively.
Irregular, often heavier bleeding is one of the hallmarks of the early perimenopause transition, and repeated heavy cycles can gradually erode ferritin stores even in women eating adequate iron-containing foods. Brain iron deficiency can occur before anaemia appears on a standard blood count, so a woman may receive a reassuring CBC result while her ferritin sits at a level (below 75 ng/mL is the threshold most RLS researchers flag) that actively starves the dopamine system. Getting a serum ferritin specifically — not just a haemoglobin — is one of the most useful first steps when RLS appears or worsens.
Night sweats, anxiety, and frequent waking from other perimenopause symptoms reduce total sleep time, and sleep deprivation itself measurably worsens RLS severity — studies show that even partial sleep restriction amplifies the sensory discomfort and the urge-to-move threshold. The relationship runs in both directions: RLS disrupts sleep, and poor sleep intensifies RLS, creating a reinforcing loop that is easy to mistake for simple insomnia. Addressing both the underlying hormonal drivers and the sleep disruption together tends to produce better outcomes than treating either in isolation.
Magnesium plays a modulatory role in NMDA receptor activity and neuromuscular excitability, and low magnesium is consistently associated with increased muscle restlessness and cramps. Estrogen helps maintain intracellular magnesium levels, so its decline can contribute to a functional magnesium insufficiency even when dietary intake hasn't changed. While the direct RLS-magnesium evidence is not as robust as the iron-dopamine story, supplemental magnesium glycinate at night is a low-risk, commonly reported option that also supports sleep quality more broadly.
SSRIs and SNRIs — frequently offered to perimenopausal women for mood changes, anxiety, or hot flushes — are well-documented RLS aggravators, thought to work by suppressing dopamine activity relative to serotonin. A woman who starts an antidepressant in perimenopause and then develops RLS within weeks may be experiencing a medication-induced symptom rather than a new primary diagnosis, a distinction that changes management entirely. This does not mean avoiding antidepressants where they are genuinely needed, but it does mean flagging the timing with a prescriber so the connection can be evaluated.
Several observational studies and smaller clinical trials have found that women using menopausal hormone therapy report meaningful reductions in RLS symptom severity, consistent with the theory that restoring estrogen and progesterone partially corrects the dopamine and sensory-excitability deficits driving the condition. Progesterone-containing regimens appear particularly relevant, given progesterone's GABAergic calming effects on spinal sensory pathways. This is an area where the evidence is not yet drawn from large RCTs, but the mechanistic logic and the clinical observations point in the same direction.
Checking and correcting ferritin to above 75 ng/mL through diet or supplementation is the single highest-yield non-hormonal intervention, supported by strong RLS research regardless of menopausal status. Avoiding known triggers — caffeine in the afternoon, alcohol, antihistamines, and vigorous exercise late in the evening — removes unnecessary dopamine interference at the time of day when RLS peaks. Regular moderate exercise earlier in the day, a consistent sleep schedule, and warm leg baths before bed are all supported by clinical guidelines as adjunct strategies that, while modest individually, can add up to meaningful relief.
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.